Poster-Disease-modifying Therapy
October 25, 2021
Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Background: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with...
Poster-Disease-modifying Therapy
October 25, 2021
Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit
Background: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of...
Poster-Disease-modifying Therapy
October 25, 2021
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...